Truxima Purple Book BLA 761088

BLA number
761088
Proprietary names
Truxima
Proper names
rituximab-abbs
Applicant
CELLTRION, Inc.
Center
CDER
First observed release
2020-02-01
Latest observed release
2026-07-01
Newest archive release
2026-07-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Truximarituximab-abbs351(k) Interchangeable100MG/10ML (10MG/ML)InjectionIntravenousSingle-Dose VialRxLicensed2018-11-28
002Truximarituximab-abbs351(k) Interchangeable500MG/50ML (10MG/ML)InjectionIntravenousSingle-Dose VialRxLicensed2018-11-28

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2026-07-01U001Truxima351(k) InterchangeableRxCELLTRION, Inc.
2026-07-01U002Truxima351(k) InterchangeableRxCELLTRION, Inc.
2021-07-01U001Truxima351(k) BiosimilarRxCELLTRION, Inc.
2021-07-01U002Truxima351(k) BiosimilarRxCELLTRION, Inc.
2021-05-01U001Truxima351(k) BiosimilarRxCelltrion
2021-05-01U002Truxima351(k) BiosimilarRxCelltrion

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2026-07-01001Truxima351(k) InterchangeableRxLicensed2018-11-28
2026-07-01002Truxima351(k) InterchangeableRxLicensed2018-11-28
2020-05-01001Truxima351(k) BiosimilarRxLicensed2018-11-28
2020-05-01002Truxima351(k) BiosimilarRxLicensed2018-11-28
2020-02-01001Truxima351(k) BiosimilarMarketedLicensed2018-11-28
2020-02-01002Truxima351(k) BiosimilarMarketedLicensed2018-11-28